

Thank you for contacting Neurocrine Biosciences with your unsolicited Medical Information request regarding the presentation of abnormal movements in tardive dyskinesia (TD) from the KINECT 3 study population.

KINECT 3 (NCT02274558) was a 6-week, randomized, double-blind, placebo-controlled trial of valbenazine (80 and 40 mg/day) in adults with tardive dyskinesia and schizophrenia/schizoaffective disorder or mood disorder. The study included medically and psychiatrically stable men and women with moderate to severe TD, based on a qualitative assessment of screening videos by external abnormal involuntary movement scale (AIMS) reviewers. AIMS baseline scores were analyzed by psychiatric diagnosis subgroup; no statistical testing between subgroups was conducted (Factor 2017, enclosed).¹

Results showed that in both diagnostic groups, the AIMS items with the highest mean scores at baseline were jaw, lips and tongue (Figure 1). Jaw (AIMS item 3) had the highest mean score (1.7) in the schizophrenia/schizoaffective group and tongue (AIMS item 4) had the highest mean score (2.1) in the mood disorder group.¹





Figure 2 showed the percentage of participants with a baseline score of ≥ 2 (mild = 2, moderate = 3, severe = 4) for each AIMS item in both schizophrenia/schizoaffective disorder and mood disorder groups. In both groups, all AIMS items had $>30\%$ of participants with a score of ≥ 2 .¹



12780 El Camino Real, San Diego, CA 92130 (858) 617-7600



This letter and the enclosed material are provided in response to your unsolicited medical information inquiry. Please feel free to contact Neurocrine Medical Information at (877) 641-3461 or medinfo@neurocrine.com if you would like to request additional information.

References:

1. Factor SA et al. Tardive Dyskinesia by Body region in Subjects with Schizophrenia/Schizoaffective Disorder or Mood Disorder: Findings from the KINECT 3 Study. Poster presented at the 21st International Congress of Parkinson’s Disease and Movement Disorders; June 4-8, 2017; Vancouver, BC, Canada.

Enclosures:

1. Factor SA et al. Tardive Dyskinesia by Body region in Subjects with Schizophrenia/Schizoaffective Disorder or Mood Disorder: Findings from the KINECT 3 Study. Poster presented at the 21st International Congress of Parkinson’s Disease and Movement Disorders; June 4-8, 2017; Vancouver, BC, Canada.